A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia

S. Lachance, A.L. Christofides, J.K. Lee, L.H. Sehn, B.C. Ritchie, C. Shustik, D.A. Stewart, C.L. Toze, E. Haddad, D.C. Vinh

Abstract


Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (cll), who typically have increased susceptibility because of hypogammaglobulinemia (hgg) related to their disease and its treatment. Immunoglobulin replacement therapy (igrt) has been shown to reduce the frequency of bacterial infections and associated hospitalizations in patients with hgg or a history of infection, or both. However, use of igrt in cll is contentious. Studies examining such treatment were conducted largely before the use of newer chemoimmunotherapies, which can extend lifespan, but do not correct the hgg inherent to the disease. Thus, the utility of igrt has to be re-evaluated in the current setting. Here, we discuss the evidence for the use of igrt in cll and provide a practical approach to its use in the prevention and management of infections.


Keywords


Chronic lymphocytic leukemia; hypogammaglobulinemia; immunoglobulins; immunoglobulin replacement therapy; infection; ivig; scig; immunodeficiency

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.23.2810






Copyright © 2017 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)